AbCellera Biologics (NASDAQ: ABCL)
AbCellera Biologics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
AbCellera Biologics Company Info
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
News & Analysis
3 Growth Stocks That Could Go Parabolic in 2024
These innovation-oriented companies could take flight this year.
1 Sector Received $6.1 Billion in AI Investments Last Year: 3 Top Stocks to Buy
These companies are leading the way in using AI in healthcare.
Why AbCellera Biologics Rallied as Much as 24% on Wednesday
The contract drug developer's stock is finally shaking off the froth of its initial public offering.
Why AbCellera Biologics Is 10% Lower Today
The company has a plan for life after COVID-19, though it pales in comparison.
Why AbCellera Biologics Stock Sank 21.6% in October
The biotech is now down roughly 56% across 2021's trading.
Why AbCellera Biologics Stock Jumped 19.4% Last Month
Despite last month's gains, the biotech stock is now down roughly 61% year to date.
Why AbCellera Biologics Stock Jumped 7% on Wednesday
The company's drug-development technology is starting to attract attention.
Here's Why AbCellera Biologics Stock Gained 10.6% Last Month
Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading.
Valuation
Earnings Transcripts
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
ABCL earnings call for the period ending December 31, 2023.
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript
ABCL earnings call for the period ending September 30, 2023.
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript
ABCL earnings call for the period ending June 30, 2023.
AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript
ABCL earnings call for the period ending March 31, 2023.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.